Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Saskatchewan

$25,000.00

Intracellular cyclic reagents for validating protein function

EF 2008-09

Résumé
Functional genomic analyses are providing data sets that allow hypotheses to be formulated on the therapeutic potential of proteins. Given the large number of protein activities and interactions that are predicted to be important for any given disease, it is difficult to determine the best targets for drug development. It is also too time consuming and expensive to initiate drug development programs against all these targets. To circumvent these problems, cost-effective methods are needed to rapidly validate targets that are important in disease-associated processes and that are susceptible to inhibition by trans dominant agents such as small-molecule drugs. The goal of this proposal is to develop a comprehensive platform for isolating cyclic peptides and antibody-like single-chain variable regions (scFvs) that interact with protein targets with high affinity and specificity. The proposal builds on previous technology developed in our laboratory, whereby we designed a novel genetic selection for rapidly isolating "lariats" that function as inhibitors of protein function. A lariat consists of a cyclic peptide or "noose" region with a covalently attached "tail" that contains a transcription activation domain. Combinatorial libraries of lariats, where the noose region is randomized, can be screened for interactions with a protein target using the yeast two-hybrid assay. In this proposal, the short-term objective is to develop methods to increase the stability and solubility of lariat peptides and scFvs. This will improve our ability to isolate these reagents against protein targets and to use them effectively as inhibitors for validating the therapeutic potential of proteins. The long-term goal of this proposal is to isolate lariats and scFvs against protein targets involved in regulating autocrine IGF-1 signaling in chronic myeloid leukemia (CML) and to use these reagents to identify novel targets to develop drugs for treating CML.
Programme
Discovery Grants Program - Individual
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
249793-2008
Name nom
Geyer, Clarence
Department département
Biochemistry
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
25000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
33
Committee name en
Molec. & Develop. Genetics
Committee name fr
Gén. moléculaire et dévelop.
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Partie
1
Nb partie
2
Application title
Intracellular cyclic reagents for validating protein function
Keyword
NA
Application summary
Functional genomic analyses are providing data sets that allow hypotheses to be formulated on the therapeutic potential of proteins. Given the large number of protein activities and interactions that are predicted to be important for any given disease, it is difficult to determine the best targets for drug development. It is also too time consuming and expensive to initiate drug development programs against all these targets. To circumvent these problems, cost-effective methods are needed to rapidly validate targets that are important in disease-associated processes and that are susceptible to inhibition by trans dominant agents such as small-molecule drugs. The goal of this proposal is to develop a comprehensive platform for isolating cyclic peptides and antibody-like single-chain variable regions (scFvs) that interact with protein targets with high affinity and specificity. The proposal builds on previous technology developed in our laboratory, whereby we designed a novel genetic selection for rapidly isolating "lariats" that function as inhibitors of protein function. A lariat consists of a cyclic peptide or "noose" region with a covalently attached "tail" that contains a transcription activation domain. Combinatorial libraries of lariats, where the noose region is randomized, can be screened for interactions with a protein target using the yeast two-hybrid assay. In this proposal, the short-term objective is to develop methods to increase the stability and solubility of lariat peptides and scFvs. This will improve our ability to isolate these reagents against protein targets and to use them effectively as inhibitors for validating the therapeutic potential of proteins. The long-term goal of this proposal is to isolate lariats and scFvs against protein targets involved in regulating autocrine IGF-1 signaling in chronic myeloid leukemia (CML) and to use these reagents to identify novel targets to develop drugs for treating CML.